Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

574 ARTÍCULOS , VIENDO DEL 556 AL 570

Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion?

Matos MJ.

Future Med Chem. 2021 Aug;13(15):1301-1309. doi: 10.4155/fmc-2021-0119. Epub 2021 Jun 17.

Induction of specific brain oscillations may restore neural circuits and be used for the treatment of Alzheimer's disease

Chan D, Suk HJ, Jackson B, Milman NP, Stark D, Beach SD, Tsai LH.

J Intern Med. 2021 Nov;290(5):993-1009. doi: 10.1111/joim.13329. Epub 2021 Jun 22.

Mitochondrial nanomedicine: Subcellular organelle-specific delivery of molecular medicines

Milane L, Dolare S, Jahan T, Amiji M.

Nanomedicine. 2021 Oct;37:102422. doi: 10.1016/j.nano.2021.102422. Epub 2021 Jun 25.

The Relationship Between the Gut Microbiome and Neurodegenerative Diseases

Zhu X, Li B, Lou P, Dai T, Chen Y, Zhuge A, Yuan Y, Li L.

Neurosci Bull. 2021 Oct;37(10):1510-1522. doi: 10.1007/s12264-021-00730-8. Epub 2021 Jul 3.

Therapeutic potential of catalpol and geniposide in Alzheimer's and Parkinson's diseases: A snapshot of their underlying mechanisms

Zhang X, Liu K, Shi M, Xie L, Deng M, Chen H, Li X.

Brain Res Bull. 2021 Sep;174:281-295. doi: 10.1016/j.brainresbull.2021.06.020. Epub 2021 Jul 1.

Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer's and Parkinson's Diseases

Jagaran K, Singh M.

Int J Mol Sci. 2021 Aug 23;22(16):9082. doi: 10.3390/ijms22169082.

Current Status and Challenges of Stem Cell Treatment for Alzheimer's Disease

Pacheco-Herrero M, Soto-Rojas LO, Reyes-Sabater H, Garcés-Ramirez L, de la Cruz López F, Villanueva-Fierro I, Luna-Muñoz J.

J Alzheimers Dis. 2021;84(3):917-935. doi: 10.3233/JAD-200863.

Exosomes in Alzheimer's Disease: From Being Pathological Players to Potential Diagnostics and Therapeutics

Soliman HM, Ghonaim GA, Gharib SM, Chopra H, Farag AK, Hassanin MH, Nagah A, Emad-Eldin M, Hashem NE, Yahya G, Emam SE, Hassan AEA, Attia MS.

Int J Mol Sci. 2021 Oct 6;22(19):10794. doi: 10.3390/ijms221910794.

Advances in Parkinson's Disease Drugs

Di Stefano A, Marinelli L.

Biomolecules. 2021 Nov 5;11(11):1640. doi: 10.3390/biom11111640.

Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases

Pérez-Olives C, Rivas-Santisteban R, Lillo J, Navarro G, Franco R.

Adv Exp Med Biol. 2021;1264:81-92. doi: 10.1007/978-3-030-57369-0_6.

Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer's Disease

Kim J.

Int J Mol Sci. 2021 Mar 13;22(6):2929. doi: 10.3390/ijms22062929.

Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases

Trudler D, Ghatak S, Lipton SA.

Int J Mol Sci. 2021 Jul 30;22(15):8196. doi: 10.3390/ijms22158196.

Insight γ-Secretase: Structure, Function, and Role in Alzheimer's Disease

Mal S, Malik U, Pal D, Mishra A.

Curr Drug Targets. 2021;22(12):1376-1403. doi: 10.2174/1389450121999201230203709.

Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials

Magham SV, Thaggikuppe Krishnamurthy P, Shaji N, Mani L, Balasubramanian S.

J Neurosci Res. 2021 Nov;99(11):2888-2905. doi: 10.1002/jnr.24933. Epub 2021 Sep 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias